Table 1.
Comparison of importance of attributes when selecting a NASH therapy between physicians and patients.2
| Comparison of importance of attributes between patients and physicians | |||
|---|---|---|---|
| Importance of attributes for patients (% of overall profile importance)2 |
Importance of attributes for physicians (% of overall profile importance) |
||
| Methodology: ACBC | Total (n = 164) | Methodology: BWS | Total (n = 121) |
| Impact on liver status (based on test results) | 28.15 | Impact on liver status | 24.87 |
| Impact on symptoms possibly linked to my liver disease | 17.78 | Progression to cirrhosis | 24.36 |
| Impact on blood sugar (diabetes) & cholesterol (LDL-C) | 14.64 | Impact on blood sugar | 16.11 |
| Impact on weight | 12.32 | Impact on cholesterol | 9.64 |
| Impact on progression to serious damage to my liver (cirrhosis) | 11.92 | Impact on frequency of visits to the doctor | 5.15 |
| Side effects: Itching | 5.18 | Impact on fatigue and stomach pain | 4.75 |
| Side effects: Diarrhoea | 4.66 | Impact on weight | 4.13 |
| Side effects: Nausea | 3.16 | Possibility to cause itching | 3.99 |
| Frequency of visits to my doctor | 1.17 | Possibility to cause diarrhoea | 2.69 |
| Side effects: Headache | 1.03 | Possibility to cause nausea | 2.18 |
| Possibility to cause headache | 2.13 | ||
NOTE: “Impact on symptoms possibly linked to my liver disease” in patient research was equivalent to “impact of fatigue and stomach pain” in physician research (language adjusted for patient understanding). NASH, non-alcoholic steatohepatitis.